Literature DB >> 25431852

Mutation in PIGA results in a CD52-negative escape variant in a Sézary syndrome patient during alemtuzumab treatment.

Constantijn J M Halkes1, Willem H Zoutman2, Leslie van der Fits2, Inge Jedema3, Maarten H Vermeer2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25431852     DOI： 10.1038/jid.2014.501

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  11 in total

1.  Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia.

Authors:  E Tuset; E Matutes; V Brito-Babapulle; R Morilla; D Catovsky
Journal:  Leuk Lymphoma       Date:  2001 Nov-Dec

2.  Circulating PIG-A mutant T lymphocytes in healthy adults and patients with bone marrow failure syndromes.

Authors:  R E Ware; C V Pickens; C M DeCastro; T A Howard
Journal:  Exp Hematol       Date:  2001-12       Impact factor: 3.084

3.  Alemtuzumab-resistant Sézary syndrome responding to zanolimumab.

Authors:  Anton B Alexandroff; Volha Shpadaruk; W Mark Bamford; D Ben J Kennedy; Robert Burd; Martin J S Dyer
Journal:  Br J Haematol       Date:  2011-04-12       Impact factor: 6.998

4.  Can the level of CD52 expression on Sézary cells be used to predict the response of Sézary syndrome to alemtuzumab?

Authors:  Iolanda Conde Fernandes; Marta Gonçalves; Maria dos Anjos Teixeira; Cristina Gonçalves; Jorge Coutinho; Manuela Selores; Rosário Alves; Margarida Lima
Journal:  J Am Acad Dermatol       Date:  2012-11       Impact factor: 11.527

5.  The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment.

Authors:  A C Rawstron; S J Rollinson; S Richards; M A Short; A English; G J Morgan; G Hale; P Hillmen
Journal:  Br J Haematol       Date:  1999-10       Impact factor: 6.998

6.  Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.

Authors:  A de Masson; P Guitera; P Brice; I Moulonguet; F Mouly; J-D Bouaziz; M Battistella; I Madelaine; J Roux; C Ram-Wolff; J-M Cayuela; H Bachelez; A Bensussan; L Michel; M Bagot
Journal:  Br J Dermatol       Date:  2014-03       Impact factor: 9.302

7.  Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.

Authors:  Christiane Querfeld; Neha Mehta; Steven T Rosen; Joan Guitart; Alfred Rademaker; Pedram Gerami; Timothy M Kuzel
Journal:  Leuk Lymphoma       Date:  2009-12

8.  Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly.

Authors:  Lapo Alinari; Larisa Geskin; Terrence Grady; Robert A Baiocchi; Mark A Bechtel; Pierluigi Porcu
Journal:  Leuk Res       Date:  2007-12-21       Impact factor: 3.156

9.  Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients.

Authors:  Maria Grazia Bernengo; Pietro Quaglino; Alessandra Comessatti; Michela Ortoncelli; Mauro Novelli; Francesco Lisa; Maria Teresa Fierro
Journal:  Haematologica       Date:  2007-06       Impact factor: 9.941

10.  Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma.

Authors:  B Hertenstein; B Wagner; D Bunjes; C Duncker; A Raghavachar; R Arnold; H Heimpel; H Schrezenmeier
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113
View more
  1 in total

Review 1.  Flow cytometry for the assessment of blood tumour burden in cutaneous T-cell lymphoma: towards a standardized approach.

Authors:  Maarten H Vermeer; Helene Moins-Teisserenc; Martine Bagot; Pietro Quaglino; Sean Whittaker
Journal:  Br J Dermatol       Date:  2022-05-03       Impact factor: 11.113
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.